ProKidney Corp. (PROK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $417.20M
Last updated: Nov 17, 2026 at 11:04 AM ET
ProKidney Corp. (PROK) Stock Forecast
Analysts expect ProKidney (PROK) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $634800. Of 6 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 66.7% |
| Hold | 1 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 16.7% |
- Consensus
- Hold
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 2.7%.
- Fiscal year ending Dec 31, 2026
- -$0.58
- EPS consensus, revenue $634800
- Fiscal year ending Dec 31, 2027
- -$0.76
- EPS consensus, revenue $617750
- Next report
- Mar 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.58 | -$0.66 to -$0.51 | 4 | $634800 | $376000 to $800000 | 5 |
| Dec 31, 2027 | -$0.76 | -$1.35 to -$0.42 | 5 | $617750 | $495000 to $800000 | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.19 to -$0.12 | 8 | $136068 | N/A | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 8 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 5 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.56.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.58 | -$0.58 | -$0.56 | -$0.56 | -$0.56 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.76 | -$0.61 | -$0.59 | -$0.59 | -$0.59 | N/A |
Frequently Asked Questions About PROK
What is the PROK stock forecast?
Consensus analyst estimates put ProKidney's EPS at -$0.58 for the fiscal year ending Dec 31, 2026, on revenue of $634800. The consensus rating from 6 analysts is Hold.
How do analysts rate PROK stock?
Of 6 analysts covering ProKidney, 0 rate it Strong Buy, 4 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PROK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.66 to -$0.51 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.76, with estimates from -$1.35 to -$0.42 from 5 analysts.
What revenue do analysts expect from ProKidney next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $634800, with estimates from $376000 to $800000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $617750, with estimates from $495000 to $800000.
How many analysts cover PROK?
6 analysts rate ProKidney stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PROK pages: Overview, Earnings, Forecast, Financials, Competitors